Publications by authors named "G Giannini"
Trimethylaminuria (TMAU) is a rare metabolic syndrome caused by the accumulation of trimethylamine in the body, causing odor emissions similar to rotten fish in affected patients. This condition is determined by both genetic and environmental factors, especially gut dysbiosis. The multifactorial nature of this syndrome makes for a complex and multi-level diagnosis.
View Article and Find Full Text PDFArticle Synopsis
- Autoantibodies against IFN-α (AAb-IFN-α) may be linked to less aggressive autoimmune behaviors in latent autoimmune diabetes in adults (LADA) compared to early-onset type 1 diabetes (T1D).
- Researchers compared the presence of AAb-IFN-α in LADA (41 subjects) versus T1D (90 subjects) to determine its clinical significance.
- Results indicated a higher positivity for AAb-IFN-α isoforms in LADA patients, suggesting a unique autoimmune profile that could inform future therapeutic approaches in autoimmune diseases.
Background: The efficacy of subthalamic stimulation on axial signs of Parkinson's disease (PD) is debated in the literature. This study delves into the dynamic interplay of gait and posture, specifically probing their nuanced response to subthalamic stimulation and levodopa.
Methods: We used wearable sensor technology to examine alterations in the spatiotemporal parameters of gait and posture in individuals with PD before and 6 months after subthalamic deep brain stimulation (STN-DBS) surgery.
The transcription factor GLI1 is the main and final effector of the Hedgehog signaling pathway, which is involved in embryonic development, cell proliferation and stemness. Whether activated through canonical or non-canonical mechanisms, GLI1 aberrant activity is associated with Hedgehog-dependent cancers, including medulloblastoma, as well as other tumoral contexts. Notwithstanding a growing body of evidence, which have highlighted the potential role of post translational modifications of GLI1, the complex mechanisms modulating GLI1 stability and activity have not been fully elucidated.
View Article and Find Full Text PDFBackground: Lu PSMA therapy is increasingly used for metastatic castration-resistant prostate cancer (mCRPC) treatment. However, data on its efficacy and safety in patients previously treated with Ra remain limited.
Methods: This retrospective, multicenter study evaluated 233 mCRPC patients treated with Lu PSMA at 5 European centers.